Action BRPA NRX PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues NRx Pharmaceuticals, Inc.

Actions

BRPA

US6294442099

Temps réel estimé Cboe BZX
Autres places de cotation
 18:45:10 29/04/2024 		Varia. 5j. Varia. 1 janv.
3,53 USD -0,28% Graphique intraday de NRx Pharmaceuticals, Inc. +21,66% -20,66%
18/04 Les fonds négociés en bourse et les contrats à terme sur actions sont en hausse avant la cloche du jeudi, dans l'attente des discours des décideurs de la Fed MT
17/04 NRx Pharmaceuticals, Inc. Annonce de nouvelles données sur le NRX-101 démontrant l'absence de dommages à la flore intestinale et vaginale dans des modèles validés de rongeurs par rapport aux antibiotiques standard CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
NRx Pharmaceuticals Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches
Top Premarket Decliners
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities; Shares Slump Premarket
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics
NRx Pharmaceuticals Announces Development of New, Proprietary Formulation of HTX-100
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
NRx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
UPDATE, NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
NRx Pharmaceutical's Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BRPA
  4. Actualités NRx Pharmaceuticals, Inc.
  5. Autres langues